1. Gomaa AI, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008: 14(27), 4300-08.
2. LLovet JM, et al.. Hepatocellular carcinoma. Lancet 2003; 352, 1907-1917.
3. Balecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. YPB (Oxford) 2005; 7, 26-34
4. Saar B, Kellner-Welldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int. 2008; 28(2), 189-199.
5. Pons F, et al. Staging systems in hepatocellulr carcinoma. HPB (Oxford) 2005; 7, 35-41.
6. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, Pa: Saunders; 1964:50.
7. Llovet JM, et al.. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30:1434-1440.
8. Mazzaferro V, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
9. Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology 2008; 134(7), 1831-35.
10. Oliveri RS, et al.. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD004787. doi:10.1002/14651858.CD004787.pub.
11. Ibrahim SM, et al. Radioembolisation for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008; 14 (11), 1664-1669.
12. Palmer D.H., et al. Systemic therapies for hepatocellular carcinoma // Expert Opin. Investig. Drugs. 2004. Vol. 13. p. 1555-1568.
13. Llovet J.M.,. Sorafenib in advanced hepatocellular carcinoma // N. Engl. J. Med. 2008. Vol. 359. p. 378—390.
14. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-1426.
15. Lok AS, McMahon BJ. Chronic hepatitis B, update 2009. AASLD Practice guidelines, Ed 2009/08/29
16. Garcia-Tsao G.S.A., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis // Hepatology. 2007. Vol. 46. p. 922-938
17. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J of Hepatology 2012 vol. 56 p 908-943
18. Villanueva A, Newell P, Chiang DY et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76
19. Edeline J, Boucher E, Rolland Y et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118: 147-156